Wedbush Securities Inc. purchased a new stake in VERONA PHARMA P/S (NASDAQ:VRNA) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 14,130 shares of the company’s stock, valued at approximately $127,000. Wedbush Securities Inc. owned 0.11% of VERONA PHARMA P/S at the end of the most recent quarter.

Separately, Foresite Capital Management IV LLC acquired a new position in shares of VERONA PHARMA P/S during the third quarter valued at approximately $104,000. Institutional investors and hedge funds own 56.33% of the company’s stock.

A number of research analysts recently commented on VRNA shares. Wedbush reiterated a “buy” rating on shares of VERONA PHARMA P/S in a research note on Monday, January 14th. Zacks Investment Research upgraded shares of VERONA PHARMA P/S from a “hold” rating to a “strong-buy” rating and set a $14.00 price target on the stock in a research report on Saturday, November 10th. Finally, ValuEngine upgraded shares of VERONA PHARMA P/S from a “hold” rating to a “buy” rating in a research report on Wednesday, November 21st. One investment analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company. VERONA PHARMA P/S presently has a consensus rating of “Buy” and an average price target of $31.33.

Shares of NASDAQ:VRNA traded up $0.18 during trading on Monday, reaching $5.90. 2,867 shares of the company traded hands, compared to its average volume of 14,882. The firm has a market capitalization of $77.47 million, a P/E ratio of -2.45 and a beta of -1.26. VERONA PHARMA P/S has a 1-year low of $5.55 and a 1-year high of $25.55.

ILLEGAL ACTIVITY NOTICE: “Wedbush Securities Inc. Purchases New Position in VERONA PHARMA P/S (VRNA)” was published by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at

VERONA PHARMA P/S Company Profile

Verona Pharma plc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics to treat respiratory diseases. The company's product candidate is RPL554, an inhaled dual inhibitor of the enzymes phosphodiesterase 3 and 4, which has completed Phase I and IIa clinical trials that acts as a bronchodilator and an anti-inflammatory agent for the treatment of chronic obstructive pulmonary disease and cystic fibrosis.

Further Reading: What is the Coverage Ratio?

Receive News & Ratings for VERONA PHARMA P/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VERONA PHARMA P/S and related companies with's FREE daily email newsletter.